Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Teva Branded Pharmaceutical Products R&D, Inc.
University of Illinois at Chicago
Emory University
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute
Teva Branded Pharmaceutical Products R&D, Inc.